Gennisium

What Gennisium does

Gennisium Pharma is a privately held French specialty pharmaceutical company founded in June 2018 by Franck Pigache and Emilie Garcin, headquartered in Vitrolles, France. The company is dedicated to the development, registration, and commercialisation of medicines for neonatology, serving Neonatal Intensive Care Units (NICUs) and healthcare practitioners who treat preterm newborns. Its methodology is to reposition known molecules into formulations and presentations specifically suited to neonatal populations and to leverage EMA Centralised Procedure hybrid drug applications to accelerate regulatory pathways.

The company's commercial portfolio centres on Gencebok® (caffeine citrate 10 mg/ml, 1 ml ampoule, solution for infusion), which received a centralised European Marketing Authorisation in August 2020 for the treatment of primary apnoea of premature newborns. Gennisium complements this asset with ProPrems®, a probiotic Food for Special Medical Purpose licensed from Neobiomics, distributed directly to French NICUs following a January 2023 DGCCRF marketing declaration. An internal pipeline targets additional neonatal indications in respiratory distress and metabolism disorders. Manufacturing, packaging, logistics, and galenic development are outsourced to a network of suppliers, while Gennisium retains in-house Regulatory Affairs, Medical, Marketing, and Commercialisation functions.

Gennisium generates revenue through three streams: (1) direct sales of its own approved medicines via an in-house sales force in key European and export countries, (2) out-licensing royalties from six regional partners (Mercapharm, AxxessBio, Nordic Prime, Global Farma, Reach-Pharma, Moksha8) covering Poland, South-East Asia, the Nordics, Central America/Caribbean/Venezuela, Oceania, and Mexico/Brazil, and (3) distribution-based revenue from the in-licensed ProPrems® product in France. Pricing is not publicly disclosed and follows a B2B pharma model directed at hospitals, NICUs, and licensees. The company received a minority strategic investment from Pierre Fabre Group (via Pierre Fabre Invest) in October 2022.

Name

Gennisium

Legal name

GENNISIUM PHARMA

Website

https://gennisium.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Gennisium Pharma is a French specialty pharmaceutical company that develops, registers, and commercialises galenic formulations of repositioned medicines for neonatology, serving NICUs and healthcare practitioners across Europe and selected export markets via its own sales force and regional out-licensing partners.

Ownership category

akta.pro rank

Product category

Neonatal Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Baby Feeding Supplements & Fortifiers (Probiotics, DHA/ARA, Vitamins) (CRADAEAI)

Keywords

• Neonatal pharmaceutical products
• Specialty pharma formulations
• Caffeine citrate injections
• Preterm infant medicines
• Drug repositioning neonatology

Headquarters

HQ city

Vitrolles

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Direct pharmaceutical product sales: Gennisium sells its approved medicines (Gencebok® and ProPrems®) through its own sales force in key European and Export countries, including direct distribution of ProPrems® to NICUs in France.
2. Out-licensing royalties: Exclusive licence agreements with regional partners (Mercapharm, AxxessBio, Nordic Prime, Global Farma, Reach-Pharma, Moksha8) for Gencebok® in specific geographies, generating royalty/licensing income from sales outside direct markets.
3. Licensed-in product distribution (ProPrems®): Gennisium holds exclusive rights from Neobiomics to register, market, and sell ProPrems® in France under a License Agreement, generating sales-based revenue from the licensed product.

Pricing tiers

Go-to-market motion2 records

Core offering

Gennisium Pharma develops, registers, and commercializes specialty medicines for neonatology by repositioning known molecules into formulations and presentations suitable for preterm infants. Its lead commercial product is Gencebok® (caffeine citrate 10 mg/ml solution for infusion, EU centrally authorized for primary apnoea of premature newborns), sold via its own sales force in Europe and out-licensed to regional distributors in other markets; it also distributes ProPrems®, a probiotic Food for Special Medical Purpose, to French NICUs under an exclusive licence from Neobiomics.

Product overview

Gennisium Pharma operates a focused, specialty-pharma portfolio rather than a multi-module software platform. Its single approved core product is Gencebok® (caffeine citrate 10 mg/ml solution for infusion, centrally authorised in the EU for primary apnoea of premature newborns), which is distributed across Europe and through out-licensing partners (Mercapharm, Nordic Prime, Reach-Pharma, Moksha8, Global Farma, AxxessBio). Layered onto this commercial asset, Gennisium markets ProPrems® in France — a Food for Special Medical Purpose (DADFMS) probiotic product it distributes under an exclusive licence from Neobiomics — alongside an internal R&D pipeline of additional neonatal formulations (respiratory distress, metabolism disorders) developed by repositioning known molecules and hybrid drug approaches for preterm infants.

Differentiator

Problem solved

Functional benefit

Brands

• Gencebok®: Caffeine citrate 10 mg/ml, 1 ml ampoule, solution for infusion; indicated for the treatment of primary apnoea of premature newborns; centrally authorised in the EU from August 2020.
• ProPrems®

Products and services

• Gencebok® Caffeine citrate 10 mg/ml solution for infusion in 1 ml ampoules, for intravenous and oral administration, indicated for the treatment of primary apnoea of premature newborns. Centrally authorised in the EU from August 2020 and positioned as a formulation more suitable for maintenance doses applied by NICU staff.
• ProPrems® Food for Special Medical Purposes (DADFMS) for preterm infants: 0.5 g sticks of powder containing three microbiotic strains (Bifidobacterium longum subsp. infantis, Streptococcus thermophilus, Bifidobacterium animalis subsp. lactis) totalling approximately 1 billion CFU per stick. A Neobiomics proprietary product; Gennisium holds exclusive rights to register, market, and sell ProPrems® in France under a Licence Agreement, manufactured according to GMP and HACCP regulations.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Lucane Pharma: Paris-based specialty pharma focused on rare metabolism disorders; founded and previously led by Gennisium's CEO Franck Pigache, with co-founder Emilie Garcin also serving in regulatory/Qualified Person roles. Operates the same 'reposition known molecules for rare/orphan populations' playbook that defines Gennisium's neonatal strategy.
• Proveca: UK-based specialty pharma developing and licensing medicines specifically for children, including formulations tailored to pediatric populations. Closely comparable to Gennisium in mission (pediatric/neonatal formulation development) and scale, with a similar mix of proprietary and in-licensed products.
• Exela Pharma Sciences: US-based specialty injectable pharma with a caffeine citrate product and a portfolio of hospital injectables for niche indications. Comparable to Gennisium in targeting NICU/hospital channels with injectable presentations of known molecules, though geographically focused on the US.

Broad incumbents

• Chiesi Farmaceutici: Privately held Italian multinational with a long-established neonatology franchise (e.g., surfactant therapies for respiratory distress) and rare-disease pipeline. Comparable to Gennisium in targeting NICU formularies, but operates at vastly larger scale with global commercial infrastructure.
• Orphan Europe (Recordati Group): Specialty pharma within Recordati dedicated to rare diseases, including pediatric metabolic disorders. Comparable as a European specialty pharma serving similar hospital/specialist channels with repositioned or orphan-designated molecules, though at significantly greater scale than Gennisium.
• Swedish Orphan Biovitrum (Sobi): Swedish-listed specialty biopharma with a focused rare-disease portfolio including pediatric and neonatal hematology/immunology indications. Comparable as a Europe-anchored rare/pediatric specialty pharma pursuing similar hospital-channel commercialization, but with broader product depth.
• Ethypharm: French specialty pharma focused on pain, addiction and critical-care medicines, including injectable hospital products. Comparable to Gennisium in geography (France-headquartered), B2B hospital sales motion, and emphasis on reformulated/repositioned molecules for specific clinical populations.
• Hikma Pharmaceuticals: Multinational specialty/generic injectable manufacturer with marketed caffeine citrate products used in NICUs. Comparable to Gennisium as a competitor in caffeine citrate and adjacent injectable hospital products, though Hikma operates at substantially larger scale with broad generic-portfolio economics.
• Neuraxpharm: European specialty pharma focused on central nervous system conditions with growing pediatric and rare-disease exposure. Comparable to Gennisium as a European-headquartered specialty pharma pursuing niche indications through repositioned formulations and out-licensing partnerships.

Emerging players

• Neobiomics: Proprietary developer of ProPrems®, the probiotic Food for Special Medical Purpose product Gennisium distributes in France under exclusive licence. Comparable as a neonatal-nutrition specialist serving the same NICU customer base, with a directly overlapping product relationship.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gennisium